Optiscan Imaging (ASX:OIL) secured ethics clearance for the use of its inVue precision surgery imaging platform in patients with breast cancer, according to a filing with the Australian Securities Exchange.
The program will test the platform in real-time, validating the removal of tumors during surgery among 50 estimated participants, the medical technology firm said in the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments